NCT04628780 · OUTCOME

Percentage of Participants With Disease Control Based on Investigator Assessment

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors · Source last updated 2024-07-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of Participants
Interval / dispersion: 95% Confidence Interval
Time frame: From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 2 years approximately)

What was measured

Disease control rate (DCR) is defined as the percentage of participants with a BOR of CR, PR, non-CR/non-PD or SD.

Analysis population: Response evaluable set included all participants who received at least one dose of study treatment and had measurable disease at baseline and at least one post baseline disease assessment.

Groups in this outcome

PF-07209960 1 mg SC

Participants with advanced or metastatic solid tumors were treated with PF-07209960 1 mg as a subcutaneous (SC) administration every 2 weeks (Q2W) for a maximum duration of 10.9 months.

PF-07209960 3 mg SC

Participants with advanced or metastatic solid tumors were treated with PF-07209960 3 mg as a SC administration Q2W for a maximum duration of 5.1 months.

PF-07209960 10 mg SC

Participants with advanced or metastatic solid tumors were treated with PF-07209960 10 mg as a SC administration Q2W for a maximum duration of 3.4 months.

PF-07209960 15 mg SC

Participants with advanced or metastatic solid tumors were treated with PF-07209960 15 mg as a SC administration Q2W for a maximum duration of 5.8 months.

PF-07209960 20 mg SC

Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.

PF-07209960 30 mg SC

Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
PF-07209960 1 mg SC	3
PF-07209960 3 mg SC	4
PF-07209960 10 mg SC	3
PF-07209960 15 mg SC	3
PF-07209960 20 mg SC	11
PF-07209960 30 mg SC	5

Reported measurements

Source class 1

Values in Percentage of Participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
PF-07209960 1 mg SC	66.7	Not reported	9.4	99.2	Not reported
PF-07209960 3 mg SC	75.0	Not reported	19.4	99.4	Not reported
PF-07209960 10 mg SC	66.7	Not reported	9.4	99.2	Not reported
PF-07209960 15 mg SC	0	Not reported	0.0	70.8	Not reported
PF-07209960 20 mg SC	45.5	Not reported	16.7	76.6	Not reported
PF-07209960 30 mg SC	40.0	Not reported	5.3	85.3	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
9.4
upper Limit
99.2
value
66.7
group Id
OG001
lower Limit
19.4
upper Limit
99.4
value
75.0
group Id
OG002
lower Limit
9.4
upper Limit
99.2
value
66.7
group Id
OG003
lower Limit
0.0
upper Limit
70.8
value
0
group Id
OG004
lower Limit
16.7
upper Limit
76.6
value
45.5
group Id
OG005
lower Limit
5.3
upper Limit
85.3
value
40.0

denoms

counts
group Id
OG000
value
3
group Id
OG001
value
4
group Id
OG002
value
3
group Id
OG003
value
3
group Id
OG004
value
11
group Id
OG005
value
5
units
Participants

description

Disease control rate (DCR) is defined as the percentage of participants with a BOR of CR, PR, non-CR/non-PD or SD.

dispersion Type

95% Confidence Interval

groups

description
Participants with advanced or metastatic solid tumors were treated with PF-07209960 1 mg as a subcutaneous (SC) administration every 2 weeks (Q2W) for a maximum duration of 10.9 months.
id
OG000
title
PF-07209960 1 mg SC
description
Participants with advanced or metastatic solid tumors were treated with PF-07209960 3 mg as a SC administration Q2W for a maximum duration of 5.1 months.
id
OG001
title
PF-07209960 3 mg SC
description
Participants with advanced or metastatic solid tumors were treated with PF-07209960 10 mg as a SC administration Q2W for a maximum duration of 3.4 months.
id
OG002
title
PF-07209960 10 mg SC
description
Participants with advanced or metastatic solid tumors were treated with PF-07209960 15 mg as a SC administration Q2W for a maximum duration of 5.8 months.
id
OG003
title
PF-07209960 15 mg SC
description
Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.
id
OG004
title
PF-07209960 20 mg SC
description
Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.
id
OG005
title
PF-07209960 30 mg SC

param Type

NUMBER

population Description

Response evaluable set included all participants who received at least one dose of study treatment and had measurable disease at baseline and at least one post baseline disease assessment.

reporting Status

POSTED

time Frame

From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 2 years approximately)

title

Percentage of Participants With Disease Control Based on Investigator Assessment

type

SECONDARY

unit Of Measure

Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice